NO20074710L - 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators - Google Patents

1H-Imidazole derivatives as cannabinoid CB2 receptor modulators

Info

Publication number
NO20074710L
NO20074710L NO20074710A NO20074710A NO20074710L NO 20074710 L NO20074710 L NO 20074710L NO 20074710 A NO20074710 A NO 20074710A NO 20074710 A NO20074710 A NO 20074710A NO 20074710 L NO20074710 L NO 20074710L
Authority
NO
Norway
Prior art keywords
imidazole derivatives
cannabinoid
receptor modulators
receptors
compounds
Prior art date
Application number
NO20074710A
Other languages
Norwegian (no)
Inventor
Herman H Van Stuivenberg
Josephus H M Lange
Bernard J Van Vliet
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20074710L publication Critical patent/NO20074710L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en gruppe 1H-imidazolderivater som er modulatorer av cannabinoid-CB2-reseptorer, fremgangsmåter for fremstilling av disse forbindelsene, nye intermediater anvendelige ved syntese av nevnte imidazolderivater, fremgangsmåter for fremstilling av disse intermediatene, farmasøytiske sammensetninger som inneholder et eller flere av disse 1H-imidazolderivatene som aktiv ingredies, så vel som anvendelse av disse farmasøytiske sammensetningene for behandling av forstyrrelser hvori cannabinoid-CB2-reseptorer er involvert. Forbindelsene har den generelle formelen (I) hvori R1-R4 har betydningene gitt i foreliggende beskrivelse.The present invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid CB2 receptors, processes for the preparation of these compounds, novel intermediates useful in the synthesis of said imidazole derivatives, processes for preparing these intermediates, pharmaceutical compositions containing one or more of them. The 1H-imidazole derivatives as active ingredient, as well as the use of these pharmaceutical compositions for the treatment of disorders involving cannabinoid CB2 receptors. The compounds have the general formula (I) wherein R1-R4 has the meanings given in the present description.

NO20074710A 2005-02-16 2007-09-14 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators NO20074710L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65309105P 2005-02-16 2005-02-16
EP05101171 2005-02-16
PCT/EP2006/060009 WO2006087355A1 (en) 2005-02-16 2006-02-16 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators

Publications (1)

Publication Number Publication Date
NO20074710L true NO20074710L (en) 2007-09-14

Family

ID=36216936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074710A NO20074710L (en) 2005-02-16 2007-09-14 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators

Country Status (9)

Country Link
EP (1) EP1874734A1 (en)
JP (1) JP2008530179A (en)
AU (1) AU2006215567B2 (en)
BR (1) BRPI0607439A2 (en)
CA (1) CA2597896A1 (en)
IL (1) IL184006A0 (en)
NO (1) NO20074710L (en)
RU (1) RU2410377C2 (en)
WO (1) WO2006087355A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007292155B2 (en) * 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
FR2908766B1 (en) * 2006-11-20 2009-01-09 Sanofi Aventis Sa PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
EP2185506A1 (en) * 2007-08-22 2010-05-19 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
MX336731B (en) 2010-01-28 2016-01-28 Harvard College Compositions and methods for enhancing proteasome activity.
DK2707101T3 (en) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc PROTEOSTASE REGULATORS
KR101970509B1 (en) * 2011-09-28 2019-04-19 후지필름 가부시키가이샤 Crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate, crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, and method for producing same
WO2013147160A1 (en) * 2012-03-29 2013-10-03 東レ株式会社 Cyclic amine derivative and use thereof for medical purposes
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
HRP20180703T1 (en) * 2013-06-12 2018-06-15 Kaken Pharmaceutical Co., Ltd. IMIDAZOLE 4-ALKINYL DERIVATIVE AND THE MEDICINAL PRODUCT AS AN ACTIVE INGREDIENT
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN107922386B (en) 2015-06-22 2021-04-02 大日本住友制药株式会社 1,4-Disubstituted imidazole derivatives
SG11201710694YA (en) * 2015-06-22 2018-01-30 Sumitomo Dainippon Pharma Co Ltd Bicyclic heterocyclic amide derivative
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
JP2021528405A (en) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． Amide-substituted thiazole as a modulator of RORγt
EP3806958B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles as modulators of roryt
ES2925473T3 (en) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORyt
CA3103770A1 (en) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
RU2725878C1 (en) * 2019-12-30 2020-07-07 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр "КОМИ научный центр Уральского отделения Российской академии наук" Chiral myrtanyl sulphonamides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA911218B (en) * 1990-06-29 1991-11-27 Sumitomo Chemical Co A 1-phyridylimidazole derivative and its production and use
HK1041264B (en) * 1998-07-23 2007-08-17 安斯泰来制药有限公司 Imidazole compounds and their use as adenosine deaminase inhibitors
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2006076202A1 (en) * 2005-01-10 2006-07-20 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands

Also Published As

Publication number Publication date
BRPI0607439A2 (en) 2010-04-06
WO2006087355A1 (en) 2006-08-24
AU2006215567A1 (en) 2006-08-24
RU2007134428A (en) 2009-03-27
CA2597896A1 (en) 2006-08-24
JP2008530179A (en) 2008-08-07
RU2410377C2 (en) 2011-01-27
IL184006A0 (en) 2007-10-31
EP1874734A1 (en) 2008-01-09
AU2006215567B2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
NO20074710L (en) 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
UY31796A (en) CONDENSED CYCLOPENTANOCARBOXYL ACID DERIVATIVES SUBSTITUTED WITH ACILAMINE AND ITS USE AS PHARMACEUTICAL PRODUCTS.
NO20051870L (en) 1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid CB1 receptor ligands
NO20083500L (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive-allosteric modulators of mGluR2 receptors
NO20064456L (en) Thiadiazolidinones as GSK-3 inhibitors
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
MX2010007587A (en) Compounds comprising a cyclobutoxy group.
EA201190004A1 (en) CONDENSED IMIDAZOLE CARBOXAMIDE AS TRPV3 MODULATORS
NO20082285L (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
BRPI0607309A2 (en) processes for the preparation of substituted phenylpyrazole urea
WO2009116074A3 (en) Substituted benzimidazoles as cannabinoid modulator
NO20065678L (en) 3- (4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors.
NO20091766L (en) Spiro-piperidine
EA200870606A1 (en) SERO-CONTAINING DERIVATIVES OF PYRAZOL AS AN ELECTORAL ANTAGONISTS OF CANA CANNABINOID RECEPTOR
MX2011006821A (en) Fused imidazole derivatives as trpv3 antagonist.
MA32479B1 (en) Compounds new active as muscarinic receptor antagonists
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
WO2008109027A3 (en) Tri-aryl/heteroaroaromatic cannabinoids and use thereof
UA100862C2 (en) Hexatomic aromatic compounds, preparation and use thereof
EA201170721A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS A CHEMOCIN RECEPTOR MODULATORS
NO20062249L (en) 1H-imidazole derivatives as cannabionide receptor modulators
EA201190003A1 (en) CHROMENON DERIVATIVES AS TRPV3 ANTAGONISTS
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
NO20091830L (en) Spiro-piperidine derivatives as VIa receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application